CLDN18 and esophageal adenocarcinoma: Although CLDN18.2 was shown to be a predictive marker in this clinical study, little is known about its expression patterns in larger, real-world patient populations, with especially esophageal adenocarcinoma being known for its heterogeneity in geographical distribution, clinical course and biology at the tissue and cell level2.